FLEX: From Genomic Profiling to Real-World Insights in 30,000 Patients with Early-Stage Breast Cancer
Publication: SABCS 2025, Presentation ID: PS5-09-19 Authors: Gold et Read More
Agendia Announces Publication in JNCI Cancer Spectrum Demonstrating that MammaPrint® Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer Using Real-World Evidence from the FLEX Study GalleryAgendia Announces Publication in JNCI Cancer Spectrum Demonstrating that MammaPrint® Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer Using Real-World Evidence from the FLEX Study
Agendia Announces Publication in JNCI Cancer Spectrum Demonstrating that MammaPrint® Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer Using Real-World Evidence from the FLEX Study
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – August 12, Read More
Genetic vs. Genomic Testing in Early-Stage Breast Cancer: What You Need to Know?
How these tests can help create a treatment plan Read More
Association of MammaPrint and Clinical Outcomes by Race Among 5000 Individuals With HR+HER2- Early-Stage Breast Cancer Enrolled in FLEX
Publication: ASCO® 2025 Authors: Erin Cobain, Priyanka Sharma, Kent Read More
Agendia to Unveil Novel Data on Genomic Risk and Treatment Disparities in Early-Stage Breast Cancer at 2025 ASCO® Annual Meeting
FLEX Study reaches milestone of 20,000 enrolled patients, providing Read More
Anthracyclines and Treatment of Early-Stage Breast Cancer
For decades, anthracyclines have played an important role in Read More
Prediction of Chemotherapy Benefit by MammaPrint in HR+HER2- Early Stage Breast Cancer Revealed by the FLEX Registry of Real World Data
Source: San Antonio Breast Cancer Symposium® Authors: Adam Brufsky*, Read More
Agendia’s FLEX Study Reaches Enrollment of Over 17,000 Early-Stage Breast Cancer Patients Across Diverse Population
This achievement highlights the remarkable seven-year progression of FLEX Read More
Agendia Achieves CE-IVDR Certification
Agendia Achieves CE-IVDR Certification for its MammaPrint and BluePrint Breast Cancer Assays
Read More
Agendia Announces JCO Publication on MammaPrint Utility in NRG/NSABP B-42 Trial
MammaPrint 70-gene Assay Evaluated in the NRG Oncology/NSABP B-42 Trial
Read More
